Inhibitory effect of medroxyprogesterone acetate on malignant growth of ovarian cancer 3AO cell line

Ovarian cancer 3AO cell line was treated with medroxyprogesterone acetate in vitro. The results showed that medroxyprogesterone acetate inhibited the growth of 3AO cell line. Three days after treatment, significant decrease in colony formation on the soft agar medium and subcutaneous transplant tumor formation in the nude mice were observed, and at the same time, C-erbB_2 expression in part of the 3AO cells decreased as analyzed by flow cytometry and immunohistochemical staining. Electron microscopic examination revealed certain degree of degeneration in part of the cells.

Concentration Changes of Medroxyprogesterone Acetate in Serum and Milk in Lactating Woman Who Used Depo Geston~

Objective To determine the concentration changes of medroxyprogesterone acetate （MPA） in serum and milk in the Chinese lactating women who used Depo Geston Methods Ten postpartum and breastfeeding women received an injectable contraceptive of Depo Geston （depo medroxyprogesterone acetate, DMPA, 150 mg/ampoule）. Serum and milk samples were collected in the 1^st, 2^st, 4^th, 6^th, 8^th 10^th and 12^th week after contraceptive injection. The concentrations of medroxyprogesterone acetate （MPA） in serum and milk were determined by radioimmunoassay. Results The highest MPA concentration in serum was observed at the 1^st week and then the level of serum MPA decreased obviously at the 2^na and 4^th week. After the 4^th week, the decline of serum MPA level slowed down. The concentration of milk MPA reached the highest level at 1^th week. But at the 2^nd week the average level of MPA in milk dropped by half The MPA concentration in the milk was changed in the range of 5.2-8.3 ng/mL in the following 10 weeks. During observation, the average ratios of concentration and area under curve （AUC） in milk/serum were both 0.55. There was a wide variation in MPA concentrations and ratios of milk/serum between subjects. Conclusion MPA concentrations maintained a certaim level at the 12^th week after DMPA injection. However, whether mather＇s intake of DMPA during feeding period has effect on children＇s growth, espcially pubertal growth, deserves further studies.

Development of Immunochemical Methods for Purification and Detection of the Steroid Drug Medroxyprogesterone Acetate

An immunochemical sol-gel-based immunoaffinity purification (IAP) method for purification and detection of the progestin drug medroxyprogesterone acetate (MPA) was developed. A polyclonal antibody (Ab) for MPA was generated, and two competitive (indirect and direct) sensitive enzyme-linked immunosorbent assays (ELISAs) for its detection were developed and implemented to determine the recovery and efficiency of the sol-gel based IAP method. The detection limits of the assays were 1.4 ± 0.2 ng·mL-1 (n = 4) and 4.0 ± 0.4 ng·mL-1 (n = 25) for the indirect and direct ELISAs, respectively. The Abs did not exhibit cross-reactivity with any other progestin or steroid hormone, with the exception of megestrol acetate, with which the Ab exhibited 76% cross-reactivity. The sol-gel IAP method successfully eliminated serum interference to a degree that enabled ELISA analysis of spiked serum samples. This method was also found fully compatible with subsequent chemical analytical methods, such as liquid chromatography followed by mass spectrometry (LC-MS/MS). The approaches developed in this study form a basis for analysis of MPA in biological samples and may be further used to study population exposure to MPA and to monitor MPA contamination in water samples.

Hypercalcemia Appeared in a Patient with Glucagonoma Treated with Octreotide Acetate Long-acting Release

PABCREATIC neuroendocrine tumours are uncommon neoplasms of the pancreas.They may cause a clinical syndrome due to hormone overproduction.Glucagonoma is a rare kind of pancreatic tumors. Here we report a case of glucagonoma. Hypercalcemia occurred when the patient underwent octreotide acetate long-acting release.

Conservative Medroxyprogesterone Acetate Therapy in Early Stage of Endometrial Carcinoma Associated with Phosphatase and Tensin Homolog Expression

Young patients with the endometrial cancer IA who desire to preserve fertility, can select the conservative therapy with progestin. However, the therapy involves risks of progression and relapse. We examined immunohistochemical analyses of phosphatase and tension homolog (PTEN) and p53 expressions to predict the early relapse, and pregnancy and delivery. Twenty women with endometrial cancer, FIGO IA (1988) (FIGO staging was essentially defined post-surgically), instead of the pathogical specimen before surgery without myometrial invasion were estimated by MRI under 40 years at Gifu University Hospital, Japan from 1988 to 2009. Patients were treated with medroxyprogesterone acetate (MPA, 400 - 600 mg/day) for 4 - 10 months, with whole wall endometrial curettage performed every four weeks. Response to the therapy, pregnancy, delivery and relapse of disease during follow-up over a 72-month period. Immunohistochemical expression of PTEN and p53 was also evaluated with pregnancy, delivery and relapse rate. All patients had pathological complete remissions within 4 - 10 months. Relapse rate was high (60%) in more than 72 months. Immunohistochemical PTEN retain in tumor cells before MPA treatment (8/10) was significant better correlation with pregnancy and delivery rate than of lost cases (1/5) in non-obese women (P < 0.05). Conservative therapy is feasible in carefully selected young women with endometrial cancer without myometrial invasion. However, the relapse rate was high. In cases who desire to be a pregnant, an earlier infertility treatment may be considered especially for PTEN loss especially in nonobese cases.

Improvement of quality of life in patients with advanced tumor underwent chemotherapy after middle-dose medroxyprogesterone administered

Objective To study the effect of medroxyprogesterone on body weight loss,myelosuppression,anorexia and quality of life(QOL)in patients with advanced neoplasm.Method37patients in group Areceived 200mg domestic medroxyprogesterone capsule,three times a day for 4consecutive weeks.37patients in group B received 500mg tablet of import medroxyprogesterone,once a day for 4consecutive weeks.Result Therapeutic effect of domestic and i mport medroxyprogesterone was simi lar of group Aand B in terms of anoxia,body weight loss,QOL(P >0.05).Side effects included abnormal liv er function,edema,and moon shaped f ace.Conclusion Medroxyprogesterone belongs to sup-portive therapy for patients with advanced tumor,which can improve QOL.Therapeutic effect of middle-dose medroxyprogesterone is satisfying.

Effect of Depot Medroxyprogesterone Acetate (DMPA) on Bone Mineral Density in Women of Reproductive Age

Objective To compare bone mineral density （BMD） between users of intramuscular depot medroxyprogesterone acetate（DMPA ） and nonhormonal control subjects. Methods The study included 68 women aged between 25 and 40 years using depot medroxyprogesterone acetate for 24 months and 59 women aged between 25 and 40 years using nonhormonal contraception as control subjects. BMD of the lumbar spine and femoral neck were obtained using dual energy X-ray absorptiometry. Results At 24 months of treatment, as compared with baseline, the mean BMD in lumbar spine and femoral neck was decreased by 5.5% and 5.9%, respectively. Lumbar spine and femoral neck BMD in women who used DMPA were significantly decreased compared with the subjects in nonuser （P〈0.001）. Conclusion These results show BMD declined during using DMPA in women aged 25 -40 years old.

Effect of depot medroxyprogesterone acetate on bone mineral density in adolescent women

Background Depot medroxyprogesterone acetate （DMPA） as a hormonal contraceptive is highly effective and widely used, but it may reduce bone mineral density （BMD） and increase the risk of osteoporosis. We compared BMD between users of intramuscular DMPA and nonhormonal subjects. Methods The study included 102 women aged between 16 and 18 years using DMPA for 24 months and 97 women aged between 16 and 18 years using nonhormonal contraception as nonusers control group. BMD of the lumbar spine and femoral neck was measured every 12 months for 24 months using dual-energy X-ray absorptiometry, comparing mean BMD changes in DMPA users and nonusers.

Clomiphene Citrate or Medroxyprogesterone Acetate with Human Menopausal Gonadotropin in Poor Responders during In vitro Fertilization/Intracytoplasmic Sperm Injection Treatments Combined with Embryo Cryopreservation?

Objective:This study aimed to compare the efficacy of clomiphene citrate(CC)with human menopausal gonadotropin(hMG)and that of medroxyprogesterone acetate(MPA)with hMG in poor responders defined according to the Bologna criteria.Methods:The data of patients with poor ovarian response(POR)according to the Bologna criteria from September 2016 to November 2017 were retrospectively reviewed.All participants received either CC+hMG or the progesterone-primed ovarian stimulation protocol(PPOS)protocol.Results:A total of 340 patients and 563 in vitro fertilization cycles were analyzed in this study.The incidence of spontaneous luteinizing hormone(LH)surge and the mean LH level on trigger day were significantly lower in the PPOS group than in the CC+HMG group(0.04%vs.3.49%and 4.26±3.59 vs.9.38±6.92 mIU/mL,respectively,P<0.05);however,the incidence of premature ovulation was similar between the two groups.The number of viable embryos harvested was not statistically different between the two groups(1.7±1.1 vs.1.5±0.8,P=0.06).The mean dose and duration of hMG were significantly higher in the PPOS group than in the CC+hMG group(908.7±556.6 vs.177.9±214.5 IU and 6.0±3.4 vs.1.2±1.5 days,respectively,P<0.05).However,the number of oocytes retrieved,number of metaphase II oocytes,and fertilization rate were comparable between the two groups.Conclusions:The CC with low-dose gonadotropin strategy was superior to the MPA with hMG protocol for POR.

Effect of depot medroxyprogesterone acetate(DMPA) on bone mineral density(BMD) and evaluating changes in BMD after discontinuation of DMPA in adolescent women

Objective To compare bone mineral density （BMD） between users of intramuscular depot medroxyprogesterone acetate （DMPA） and nonhormonal subjects and evaluated the changes in BMD after discontinuation of DMPA.Methods The study included 102 women aged 16-18 years using DMPA for 24 months and 97 same-age nonusers. BMD of the lumbar spine and femoral neck were measured using dual-energy X-ray absorptiometry. The mean BMD values were compared between DMPA users （DMPA group） and nonusers （control group） and the changes of BMD during 36 months after discontinuation of DMPA were observed.Results Mean BMD at the spine and femoral neck did not differ significantly between DMPA group and control group over 12 months, but the BMD values at both anatomical sites were significantly lower in DMPA group than in control group after 24 months treatment. After DMPA discontinuation, the mean BMD values in DMPA users increased substantially. At 24 months after DMPA discontinuation, there were no significant differences between DMPA group and control group. But the values of the lumbar spine and femoral neck BMD in DMPA group were still 1.70% and 1.87%, respectively, below nonusers at 36 months after DMPA discontinuation.Conclusion The use of DMPA for short-term （ ≤12 months） had no significant effects on BMD at spine and femoral neck, but long-term exposure to DMPA had significant loss in BMD in adolescents. Bone loss occurring with DMPA use is reversible after DMPA discontinuation.

Changes in bone mineral density among women aged 19-24 years using injectable contraceptive depot medroxyprogesterone acetate

Objective To compare bone mineral density （BMD） between users of intramuscular depot medroxyprogesterone acetate （DMPA） and nonhormonal control subjects. Methods The study included 87 women aged between 19 and 24 years using DMPA （DMPA group）for 24 months and 83 same-age women using nonhormonal contraception as control group. BMD of the lumbar spine and femoral neck were measured using dual-energy X-ray absorptiometry, comparing mean BMD changes in DMPA group with the control. Results After 24 months of DMPA treatment, as compared ~ith baseline, the mean BMD in lumbar spine and femoral neck were decreased by 2.67% and 2.71%, respectively. The mean lumbar spine and femoral neck BMD in DMPA group at 24 months were not significantly different compared with baseline （P=0. 080 and P=0. 076, respectively）. In comparison, in control group, there was a trend toward increasing BMD. After 24 months of observation, the mean percentage changes from baseline in lumbar spine and femoral neck BMD were increased by 1.24% and 1.30%, respectively. There was no significantly difference compared with baseline （P=0. 436 and P=0.373, respectively）. Mean BMD at the spine and femoral neck did not differ significantly between DMPA users and nonusers over 12 months （P=0.153 and P=0.140, respectively）, but the BMD at both anatomical sites was significantly lower in DMPA group than in the control after 24 months of treatment （P=0.012 and P=0.008, respectively）. Conclusion The use of DMPA for short-term （≤12-month） had no significant effects on BMD at spine and femoral neck, but long-term exposure to DMPA had significant loss in BMD in women aged between 19 and 24 years.

高孕激素状态下促排卵方案中不同孕激素对卵巢储备功能减退患者的应用效果比较

目的探讨卵巢储备功能减退(DOR)患者高孕激素状态下促排卵(PPOS)方案中使用醋酸甲羟孕酮(MPA)和地屈孕酮(DYG)的促排卵效果和实验室结局的差异。方法采用回顾性队列研究方法,收集2022年1月至2023年5月在山西省运城市中心医院生殖医学科采用PPOS方案行常规体外受精(IVF)/卵胞浆内单精子注射(ICSI)助孕的DOR患者的临床资料。共纳入299个周期,根据使用孕激素制剂不同分成MPA组(177个周期)和DYG组(122个周期),比较两组患者的一般资料、促排卵效果及实验室结局。结果两组患者间年龄、体质量指数(BMI)、不孕年限、基础窦卵泡数(AFC)、基础性激素[卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E_(2))]水平、ICSI周期占比、周期次数、人绝经期促性腺激素(HMG)天数、HMG总量、HCG日血清LH水平、获卵数、成熟卵率、正常受精率、可用胚胎数、优质胚胎数等比较均无显著性差异(P>0.05);相对于DYG组,MPA组早发LH峰发生率(1.12%vs.6.55%)、HCG日血清E_(2)水平(5732.98 pmol/L vs.6758.45 pmol/L)和孕酮水平(1.97 nmol/L vs.2.07 nmol/L)、孕激素费用(9元vs.90元)均显著降低(P<0.05)。结论对于DOR患者,PPOS方案中使用MPA和DYG均可获得良好的实验室结局,但MPA能够更有效降低早发LH峰发生率,可能是DOR患者PPOS方案的优选孕激素。

醋酸甲羟孕酮联合化疗治疗子宫内膜癌术后患者的临床疗效

目的探讨醋酸甲羟孕酮联合化疗治疗子宫内膜癌术后患者的临床疗效。方法根据腹腔镜手术后治疗方法的不同将98例子宫内膜癌患者分为对照组(n=49,单纯化疗)和观察组(n=49,醋酸甲羟孕酮联合化疗)。比较两组患者的肿瘤标志物[肿瘤特异性生长因子(TSGF)、X连锁凋亡抑制蛋白(XIAP)、肿瘤坏死因子-α(TNF-α)]水平、性激素[雌二醇(E_(2))、睾酮(T)、卵泡刺激素(FSH)、黄体生成素(LH)、催乳素(PRL)、性激素结合球蛋白(SHBG)]水平、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]、不良反应发生情况、复发率及复发间隔时间。结果治疗后,两组患者TSGF、XIAP、TNF-α、E_(2)水平均低于本组治疗前,观察组患者TSGF、XIAP、TNF-α、E_(2)水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者认知功能、躯体功能、情绪功能、社会功能评分均高于本组治疗前,观察组患者认知功能、躯体功能、情绪功能、社会功能评分均高于对照组,差异均有统计学意义(P<0.05)。两组患者骨髓抑制、胃肠道反应、肝肾功能异常发生率比较,差异均无统计学意义(P>0.05)。随访6个月,观察组患者的复发率低于对照组,复发间隔时间长于对照组,差异均有统计学意义(P<0.05)。结论醋酸甲羟孕酮联合化疗治疗子宫内膜癌术后患者的临床疗效较好,可降低肿瘤标志物水平和复发率,提高生活质量,且安全性较好。

左炔诺孕酮宫内节育系统与醋酸甲羟孕酮分别联合经宫颈子宫内膜电切术治疗围绝经期异常子宫出血的临床效果比较

目的比较左炔诺孕酮宫内节育系统与醋酸甲羟孕酮分别联合经宫颈子宫内膜电切术(TCRE)治疗围绝经期异常子宫出血患者的临床效果。方法选取2019年4月至2023年4月浙江省绍兴市中心医院医共体总院收治的86例围绝经期异常子宫出血患者作为研究对象。根据随机数字表法将其分为联合组(左炔诺孕酮宫内节育系统联合TCRE)与孕酮组(醋酸甲羟孕酮联合TCRE),各43例。比较两组治疗第3个月的疗效,术前及术后第3个月的月经情况(月经周期、月经时间)、血液指标、性激素指标,统计术后3个月内再出血率及药物不良反应发生情况。结果治疗第3个月,联合组疗效显著优于孕酮组,差异具有统计学意义(P<0.05);术后第3个月,两组月经周期较术前显著增加,月经时间显著缩短,且联合组均显著优于孕酮组,差异具有统计学意义(P<0.05);术后第3个月,两组血红蛋白(Hb)、D-二聚体及纤维蛋白原(FIB)水平均显著上升,且联合组均显著高于孕酮组,差异具有统计学意义(P<0.05);术后第3个月,两组雌二醇(E_(2))、卵泡刺激素(FSH)及黄体生成素(LH)均显著下降,且联合组均显著低于孕酮组,差异具有统计学意义(P<0.05);联合组术后3个月内再出血率显著低于孕酮组,差异具有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论与醋酸甲羟孕酮联合TCRE比较,左炔诺孕酮宫内节育系统联合TCRE可显著提升围绝经期异常子宫出血患者的临床疗效,更利于月经、性激素及血液指标恢复,术后再出血风险低,安全性好。

醋酸甲羟孕酮、米非司酮治疗功能性子宫出血的效果分析

目的:分析醋酸甲羟孕酮、米非司酮治疗功能性子宫出血的效果。方法:选取2021年10月—2022年9月东明县妇幼保健计划生育服务中心收治的功能性子宫出血患者200例作为研究对象,采取随机数字分组方式分为对照组与观察组,各100例。对照组给予醋酸甲羟孕酮片治疗,观察组给予米非司酮片治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。观察组不良反应总发生率低于对照组,差异有统计学意义(P=0.003)。观察组控制出血时间、完全止血时间短于对照组,差异有统计学意义(P<0.001)。治疗后,两组雌二醇、黄体生成素及孕酮水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:米非司酮治疗功能性子宫出血的效果较好,可快速改善患者出血情况,调节雌激素水平,且安全性好,值得推广使用。

围绝经期异常子宫出血采用醋酸甲羟孕酮片治疗的临床分析

目的探究醋酸甲羟孕酮片治疗围绝经期异常子宫出血的有效性。方法选取2021年10月—2023年10月中山火炬开发区人民医院的80例围绝经期异常子宫出血患者作为研究对象,使用掷骰子法分组方式,控制组和参比组各40例。前者行醋酸甲羟孕酮片治疗,后者行米非司酮治疗,对比两组效果。结果治疗后,与参比组相比,控制组控制出血时间、完全止血时间更短,差异有统计学意义(P均<0.05)。控制组子宫内膜厚度小于参比组,红细胞比容、血红蛋白大于参比组,差异有统计学意义(P均<0.05)。控制组雌二醇、卵泡刺激素、促黄体生成素、孕酮均小于参比组,差异有统计学意义(P均<0.05)。控制组不良反应发生率为5.00%,小于参比组的25.00%,差异有统计学意义(χ^(2)=6.274,P<0.05)。结论围绝经期异常子宫出血应用醋酸甲羟孕酮片治疗效果好,可改善临床指标。

葆宫止血颗粒联合醋酸甲羟孕酮治疗围绝经期异常子宫出血(阴虚血热证)的效果观察

目的评价葆宫止血颗粒联合醋酸甲羟孕酮(MPA)治疗围绝经期异常子宫出血(AUB)(阴虚血热证)的临床效果。方法前瞻性纳入海南现代妇女儿童医院2022年3月—2023年2月收治的146例围绝经期AUB(阴虚血热证)患者,采用随机数字表法分为对照组(73例)和联合组(73例)。对照组患者口服MPA,每次10 mg,每天2次;联合组患者在对照组基础上加服葆宫止血颗粒,每次15 g,每天3次。两组患者均从月经第5天开始用药,连续用药22 d作为1个治疗周期,均连续治疗2个周期,并随访12个月。比较两组患者的出血控制时间、完全止血时间、子宫内膜厚度、总有效率、复发率、中医证候评分、性激素和炎症因子水平,以及不良反应发生情况。结果联合组患者治疗后的出血控制时间、完全止血时间均显著短于对照组(P<0.05),经血色淡或有块、小腹疼痛、面色萎黄及神疲气短评分均显著低于对照组(P<0.05);治疗后1、3、6、12个月的总有效率均显著高于对照组(P<0.05),12个月内总体复发率显著低于对照组(P<0.05)。与治疗前相比,两组患者治疗后的子宫内膜厚度、血清性激素[卵泡刺激素、雌二醇和黄体生成素]、炎症因子[白细胞介素6和肿瘤坏死因子α]水平均显著减小或降低(P<0.05),而联合组较对照组的减小或下降幅度更大(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论葆宫止血颗粒联合MPA治疗围绝经期AUB(阴虚血热证)疗效确切,可快速止血、抑制子宫内膜增生、调节血清性激素和炎症因子水平,且复发率低、安全性高。

戈舍瑞林联合安宫黄体酮治疗子宫内膜异位症的效果及对血清生长因子、肿瘤标志物水平的影响

目的探讨分析戈舍瑞林联合安宫黄体酮治疗子宫内膜异位症的效果及对血清生长因子、肿瘤标志物水平的影响。方法选择2021年6月至2023年6月乳山市中医院收治的76例子宫内膜异位症患者,随机分为对照组(安宫黄体酮)与观察组(戈舍瑞林联合安宫黄体酮)各38例,比较分析两组治疗情况。结果观察组治疗总有效率高于对照组(P<0.05);治疗后观察组黄体生成素(LH)、雌二醇(E_(2))、促卵泡激素(FSH)水平低于对照组(P<0.05);治疗后观察组血清肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、上皮中性粒细胞激活肽78(ENA-78)水平低于对照组(P<0.05);治疗后观察组血管内皮生长因子(VEGF)、癌胚抗原(CEA)、糖类抗原125(CA125)水平低于对照组(P<0.05)。结论戈舍瑞林联合安宫黄体酮治疗子宫内膜异位症可提高疗效,促进患者性激素、炎症指标改善,也能调节血清生长因子、肿瘤标志物水平,值得推广。

醋酸甲羟孕酮联合戊酸雌二醇治疗功能失调性子宫出血患者的临床疗效评价

目的探讨醋酸甲羟孕酮联合戊酸雌二醇治疗功能失调性子宫出血患者的临床疗效。方法选取58例功能失调性子宫出血患者,利用随机数字表法分为对照组与研究组,每组29例。对照组患者给予醋酸甲羟孕酮片治疗,研究组患者给予醋酸甲羟孕酮片联合戊酸雌二醇片治疗。比较两组患者的临床疗效。结果研究组患者的治疗总有效率为93.10%(27/29),对照组患者的治疗总有效率为72.41%(21/29),研究组患者的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。研究组患者控制出血时间、完全止血时间均明显短于对照组,差异有统计学意义(P<0.05)。研究组的不良反应发生率为13.79%,对照组的不良反应发生率为37.93%,研究组患者的不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论醋酸甲羟孕酮联合戊酸雌二醇治疗功能失调性子宫出血患者疗效确切,缩短控制出血时间、完全止血时间,具有安全性,值得临床推广。

醋酸甲羟孕酮片联合宫腔镜手术治疗子宫内膜息肉的效果

目的探讨醋酸甲羟孕酮片联合宫腔镜手术治疗子宫内膜息肉的临床效果。方法选取本院500例子宫内膜息肉患者为研究对象,随机分为两组,各250例。对照组采用宫腔镜子宫内膜息肉切除术治疗,试验组在对照组基础上加以醋酸甲羟孕酮片治疗,比较两组月经量、子宫内膜厚度、性激素指标及复发率。结果术后6个月,试验组月经量少于对照组,子宫内膜厚度小于对照组,差异有统计学意义(P<0.05);试验组术后3个月、术后6个月孕酮水平高于对照组,差异有统计学意义(P<0.05);术后6个月,试验组复发率为1.20%,低于对照组的19.60%,差异有统计学意义(P<0.05)。结论醋酸甲羟孕酮片联合宫腔镜手术治疗子宫内膜息肉,可减少患者月经量,降低子宫内膜厚度,改善患者孕酮水平,且复发率低,安全可靠。